Daily Stock Analysis, AVXS, AveXis Inc, priceseries

AveXis Inc. Daily Stock Analysis
Stock Information
Open
117.87
Close
119.53
High
121.10
Low
117.87
Previous Close
116.70
Daily Price Gain
2.83
YTD High
128.00
YTD High Date
Jan 31, 2018
YTD Low
96.99
YTD Low Date
Jan 5, 2018
YTD Price Change
9.04
YTD Gain
8.18%
52 Week High
128.00
52 Week High Date
Jan 31, 2018
52 Week Low
53.94
52 Week Low Date
Feb 23, 2017
52 Week Price Change
64.64
52 Week Gain
117.76%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 27. 2017
58.07
Mar 21. 2017
73.01
16 Trading Days
25.74%
Link
LONG
Apr 17. 2017
73.18
May 8. 2017
77.66
15 Trading Days
6.13%
Link
LONG
Dec 13. 2017
98.34
Jan 3. 2018
106.71
13 Trading Days
8.51%
Link
Company Information
Stock Symbol
AVXS
Exchange
NasdaqGS
Company URL
http://www.avexis.com
Company Phone
972-725-7797
CEO
Sean P. Nolan
Headquarters
Illinois
Business Address
2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN, IL 60015
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001652923
About

AveXis, Inc. operates as a clinical-stage gene therapy company that engages in the research and development of technology specifically for neurological genetic disease treatment. Its proprietary gene therapy candidate, AVXS-101 has been granted orphan drug designation for the treatment of all types of spinal muscular atrophy and fast track designation for the treatment of spinal muscular atrophy type 1. The company was founded by John D. Harkey, Jr. in 2010 and is headquartered in Chicago, IL.

Description

Early-stage biotech developing gene therapy for spinal muscular atrophy.